MedTrace Logo

Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran

NCT04197323 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-12-18

No results posted yet for this study

Summary

This is a randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial

Conditions

Interventions

DRUG

Alprostadil liposomes for injection

40ug,once a day,continuous administration for 2 weeks

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04197323 on ClinicalTrials.gov